1. Introduction {#sec1-ijerph-17-04433}
===============

Regarding public health, anemia or iron deficiency anemia (IDA) is one of the indicators of nutritional deficiency status. Anemia is defined as a decrease in red blood cell numbers or the hemoglobin level, which in turn reduces the oxygen-carrying capacity of blood \[[@B1-ijerph-17-04433]\]. The worldwide prevalence of anemia has been estimated at 48% in preschool-aged children, 25% in school-aged children, 13% in males aged 15--59, 42% in pregnant women, 30% in reproductive aged women, and 24% in the elderly \[[@B2-ijerph-17-04433]\]. The causes of anemia include infections (e.g., tuberculosis, malaria, HIV), micronutrient deficiencies (e.g., of iron, folate, and vitamins A/B12/C), and genetic conditions (e.g., sickle-cell disease and thalassemia).

Almost 50% of all cases of anemia are attributable to iron deficiency, which is the most prevalent nutritional deficiency, affecting an estimated 2 billion people worldwide \[[@B3-ijerph-17-04433]\]. In South Korea, the prevalence of iron deficiency in females is 17.2%, 24.1%, 33.0%, and 5.7% in ages 10--14, 15--17, 18--49, and ≥70 years, respectively. In males, the prevalence is 8.6%, 3.9%, and 2.6% in ages 10--14, 15--17, and ≥70 years, respectively \[[@B4-ijerph-17-04433]\]. Iron deficiency anemia (IDA) not only causes adverse health outcomes, such as weakness (impairments in innate immunity/cell-mediated immunity) \[[@B5-ijerph-17-04433]\], poor physical growth, and increased risks during pregnancy (preterm delivery and inferior neonatal health) \[[@B6-ijerph-17-04433]\], but also reductions in the work capacity and productivity of both adolescents and adults \[[@B7-ijerph-17-04433]\].

In 2010, the overall IDA prevalence was 4.3% in Korea (0.7 and 8.0% in males and females, respectively) \[[@B8-ijerph-17-04433]\]. A total of 31.4% of the population with iron deficiency was found to be pregnant women, and the prevalence in elderly women was higher than that of men \[[@B9-ijerph-17-04433]\]. In particular, it was observed that women in childbearing age were underweight and were often accompanied by dietary iron deficiency \[[@B10-ijerph-17-04433]\]. However, the IDA prevalence varies by sex and age, being affected by various factors. No large-scale nationwide study has yet been performed in Korea, and we analyzed long-term trends in IDA using national claims data. The present study is a population-based nationwide study of the epidemiological burdens imposed by IDA. We estimate annual IDA prevalence rates by sex and age and the trends therein (annual percentage changes, APCs). We also calculate the health expenditures of IDA and its co-morbidities by analyzing claims data in the National Health Information Database (NHID).

2. Materials and Methods {#sec2-ijerph-17-04433}
========================

2.1. Study Subjects {#sec2dot1-ijerph-17-04433}
-------------------

Our institutional review board approved our data collection and analysis (approval no. SCHBC 2015-09-001-004). The annual prevalence, health expenditures, and co-morbidities associated with IDA were investigated using nationwide NHID data from 2002 to 2013. IDA was diagnosed based on the International Classification of Disease 10th Revision; we included all relevant codes (D50 Iron deficiency anemia, D50.0: Iron deficiency anemia secondary to blood loss (chronic), posthemorrhagic anemia (chronic), D50.8: Iron deficiency anemia, and D50.9: Iron deficiency anemia, unspecified) regardless of whether IDA was the principal, or a coexisting, disease. The numbers of the sample cohort population were as follows ([Table 1](#ijerph-17-04433-t001){ref-type="table"}).

2.2. Data Resources {#sec2dot2-ijerph-17-04433}
-------------------

### 2.2.1. The National Health Information Database {#sec2dot2dot1-ijerph-17-04433}

We used data from the NHID of the National Health Insurance Service (NHIS), which covers all Korean citizens under two major programs of NHI and Medical Aid (MA). Almost all individuals pay a proportion of their healthcare costs; the proportion varies by institution and type of care. Under MA, the government pays all medical expenses of low-income households who cannot pay for healthcare. Commencing in 2004, MA was expanded to include patients with rare, inveterate, and chronic diseases, and all children aged \<18 years \[[@B11-ijerph-17-04433]\]. In total, 97% of Koreans are covered by the NHIS and 3% by MA \[[@B12-ijerph-17-04433]\]. The NHID thus contains data on the entire Korean population, facilitating population-based nationwide studies that can precisely determine disease patterns. The NHID contains data on the claims of medical providers, including diagnoses, treatments, and services rendered, as well as on the inpatient and outpatient drugs prescribed \[[@B13-ijerph-17-04433]\].

### 2.2.2. The Korean National Health and Nutritional Examination Survey (KNHANES) {#sec2dot2dot2-ijerph-17-04433}

The KNHANES is a national surveillance system assessing the health and nutrition of Koreans. The surveys are implemented by the Korea Centers for Disease Control and Prevention, as mandated in the National Health Promotion Act. For the KNHANES, nationwide cross-sectional studies have been performed annually since 1998. The KNHANES yields objective, standardized data on disease epidemiology, socioeconomic status, health behaviors, and healthcare service utilization; these basic data inform national healthcare policies \[[@B14-ijerph-17-04433]\]. The two-way travel costs of outpatients and inpatients are also captured. Here, we use the daily travel costs when visiting clinics as reported in KNHANES IV (2009), V (2010--2012), and VI (2013).

### 2.2.3. Korean Statistical Information Service (KOSIS) {#sec2dot2dot3-ijerph-17-04433}

Statistics Korea (KOSTAT) makes various statistical data available through KOSIS, which published 86,221 statistical tables covering 756 topics in 2015. The population data (including those by sex and age) were applied herein to calculate IDA prevalence.

### 2.2.4. Prevalence of IDA {#sec2dot2dot4-ijerph-17-04433}

The annual prevalence of IDA was calculated by dividing the number of cases by the annual, residence-registered mid-year population, as recorded by KOSIS \[[@B15-ijerph-17-04433]\]. Cases of recurrence associated with retreatment during the survey year were regarded as new cases; if any such case continued into the following year, it was excluded from that later year. Prevalence rates by sex and age were derived by calculating age-standardized rates (ASRs) from 2002 to 2013. Furthermore, trends in IDA prevalence rates were evaluated by calculating APCs in prevalence \[[@B16-ijerph-17-04433]\]: $$ASRs = \frac{\sum a_{i}w_{i}}{\sum w_{i}}$$ where *a~i~* is the age-specific rate of the *i*-th age group and *W~i~* is the size of the *i*-th age group in the standard population. $$APC = (e^{b} - 1) \times 100$$ where *b* is the slope of the regression of the natural logarithm of the ASR in that year.

### 2.2.5. Health Expenditures of IDA {#sec2dot2dot5-ijerph-17-04433}

The health expenditures of IDA (direct medical and non-medical costs) were evaluated using the NHID, KNHANES, and KOSIS databases. We calculated outpatient and hospital costs (paid by both the insurer and patients), the costs of pharmaceuticals obtained in hospitals/pharmacies, and travel costs, using formulae reported previously \[[@B17-ijerph-17-04433],[@B18-ijerph-17-04433]\].

### 2.2.6. Direct Medical Cost {#sec2dot2dot6-ijerph-17-04433}

Direct medical costs were calculated with NHID data paid by the insurer or patient. Direct medical costs include outpatient and hospitalization costs and pharmaceutical costs. Patients paid 20.5% of their clinic/hospital costs and 2.9% of their pharmaceutical costs \[[@B16-ijerph-17-04433],[@B19-ijerph-17-04433]\]. $$\text{Direct\ medicial\ cost} = {\sum\limits_{i}\sum\limits_{j}}\left( \frac{OE_{ij}}{1 - \alpha} \right) + \frac{E_{ij}}{1 - \beta} + \frac{ED_{ij}}{1 - \gamma}$$ $${where}\left\{ \begin{array}{l}
{i = 0,1,\ldots,{age}} \\
{j = 1,2,{sex}} \\
{\alpha = \text{proportion\ of\ non-insured\ costs\ paid\ by\ patients\ for\ visiting\ clinics}} \\
{\beta = \text{proportion\ of\ non-insured\ costs\ paid\ by\ patients\ for\ hospitalization}} \\
{\gamma = \text{proportion\ of\ non-insured\ costs\ paid\ by\ patients\ for\ buying\ medicines}} \\
{{OE}_{ij} = \text{amonut\ claimed\ for\ visting\ clinics}} \\
{E_{ij} = \text{amount\ claimed\ for\ hospitalization}} \\
{{ED}_{ij} = \text{amount\ claimed\ for\ buying\ medicines}} \\
\end{array} \right.$$

### 2.2.7. Direct Non-Medical Cost {#sec2dot2dot7-ijerph-17-04433}

Direct non-medical costs included travel expenses to and from the outpatient clinic or hospital. The average round-trip expenses were 1.25 United States Dollars (USD) and 5.64 United States Dollars, respectively \[[@B20-ijerph-17-04433]\]. These costs were multiplied by the annual inflation rate recorded by KOSIS. Those aged \<20 or \>64 years were assumed to visit with a guardian, and their travel costs were thus doubled \[[@B16-ijerph-17-04433]\].

### 2.2.8. Co-Morbidities of IDA {#sec2dot2dot8-ijerph-17-04433}

The 10 most frequent IDA co-morbidities were ranked in both males and females.

2.3. Statistical Analyses {#sec2dot3-ijerph-17-04433}
-------------------------

The APCs of IDA were calculated using linear regression to allow evaluation of trends. The prevalence rates of co-morbidities were estimated via linear-by-linear association. All statistical analyses were performed using SPSS (ver. 24.0; IBM Corp., Armonk, NY, USA) and R (ver. 3.1.3; R Foundation for Statistical Computing, Vienna, Austria) software, and a two-tailed *p*-value \< 0.05 was considered significant.

3. Results {#sec3-ijerph-17-04433}
==========

3.1. Prevalence of IDA {#sec3dot1-ijerph-17-04433}
----------------------

Growing children and pregnant and lactating women have the highest demand of Fe and bioavailability is severely compromised in old age. The prevalence rate by sex and age were as follows ([Figure 1](#ijerph-17-04433-f001){ref-type="fig"}, [Table 2](#ijerph-17-04433-t002){ref-type="table"}, [Table 3](#ijerph-17-04433-t003){ref-type="table"}).

### 3.1.1. Prevalence by Sex {#sec3dot1dot1-ijerph-17-04433}

The overall IDA prevalence in both sexes increased approximately 2.3-fold from 2002 to 2013; the average APC was +7.6%. The prevalence in females increased 2.3-fold over the 12-year period and was always higher than in males. The IDA prevalence in males increased 2.5-fold during the same period. The APC of males (+8.9%) was higher than that of females (+7.4%) ([Figure 1](#ijerph-17-04433-f001){ref-type="fig"}, [Table 2](#ijerph-17-04433-t002){ref-type="table"}).

The female-to-male prevalence ratios (PRRs) from 2002 to 2013 were ≥1 in subjects in the second-to-seventh decades of life. On the contrary, the PRRs in children aged \<10 years were \<1 in all years, and IDA was more prevalent in males than females. The PRRs in those aged ≥80 years were \<1 until 2010, but reversed in 2011, becoming more prevalent in females thereafter ([Table 3](#ijerph-17-04433-t003){ref-type="table"}).

### 3.1.2. Prevalence by Age {#sec3dot1dot2-ijerph-17-04433}

The prevalence of IDA was highest in females aged 30--39 and 40--49 years. The APC was highest in those aged \<10 years (+18.2%), followed by those aged ≥80 (+14.7%) and 70--79 (+9.8%) years. ([Figure 1](#ijerph-17-04433-f001){ref-type="fig"}B, [Table 2](#ijerph-17-04433-t002){ref-type="table"})

The prevalence of IDA in males increased over the period 2002--2013 in all age groups. The prevalence rates were highest in infants, toddlers, preschool children aged \<10 years, and those aged ≥80 years. The APC was highest in those aged \<10 years (+19.1%), followed by those aged ≥80 years (+10.5%) ([Figure 1](#ijerph-17-04433-f001){ref-type="fig"}C, [Table 2](#ijerph-17-04433-t002){ref-type="table"}).

3.2. Health Expenditures of IDA {#sec3dot2-ijerph-17-04433}
-------------------------------

### 3.2.1. Total Treatment Costs {#sec3dot2dot1-ijerph-17-04433}

The total health expenditure increased 2.8-fold from \$210,203 in 2002 to \$596,256 in 2013. Outpatient treatment became more common over time, and hospitalization less so. The gap between outpatient and hospitalization costs widened after 2005; the total outpatient cost in 2013 was 6.2-fold that of hospitalization. The hospitalization costs per capita were higher than the outpatient costs in all years. The per-capita cost of hospitalization increased notably from 2012 ([Figure 2](#ijerph-17-04433-f002){ref-type="fig"}A, [Table 4](#ijerph-17-04433-t004){ref-type="table"}).

### 3.2.2. Direct Medical Costs {#sec3dot2dot2-ijerph-17-04433}

The total direct medical cost increased approximately 2.9-fold over the 12-year study period. The costs incurred by both insurers and patients were greater than those of pharmaceuticals prescribed in either hospitals or pharmacies, and this gap was wider in 2013 than 2002 ([Figure 2](#ijerph-17-04433-f002){ref-type="fig"}B, [Table 4](#ijerph-17-04433-t004){ref-type="table"}).

### 3.2.3. Direct Non-Medical Costs {#sec3dot2dot3-ijerph-17-04433}

Total, direct non-medical costs increased 2.4-fold from \$11,221 in 2002 to \$27,099 in 2013. The direct non-medical costs for outpatients increased 5.5-fold from \$4760 in 2002 to \$26,093 in 2013, but hospitalization costs decreased 6.4-fold from \$6461 in 2002 to \$1005 in 2013 ([Figure 2](#ijerph-17-04433-f002){ref-type="fig"}B, [Table 4](#ijerph-17-04433-t004){ref-type="table"}).

3.3. Co-Morbidities {#sec3dot3-ijerph-17-04433}
-------------------

Acute upper respiratory tract infections (URIs) were the most prevalent comorbidity in both females (95%) and males (96.4%). For male, gastrointestinal diseases (94.2%) were ranked second and other upper respiratory problems (93.0%) were ranked third. In the case of females, infectious diseases (92.5%) were ranked second, and other upper respiratory diseases (91.4%) were ranked third. Dermatitis and eczema (84% and 86.2%), and disorders of the conjunctiva (71.3% and 67.3%), were the next most common comorbidities in females and males, respectively ([Figure 3](#ijerph-17-04433-f003){ref-type="fig"}).

4. Discussion {#sec4-ijerph-17-04433}
=============

We present interesting insights into annual changes in IDA prevalence from 2002 to 2013 by sex and age, and the associated health expenditures and co-morbidities. Despite improvements in public health facilities and the development of iron-fortified foods, the prevalence of IDA is still at a level of public health concern in all sexes and ages. Notably, annual IDA prevalence has increased most rapidly over the last 12 years in those aged \<10 years, followed by those aged ≥80 and 70--79 years, of both sexes. Females aged 30--49 years are also at highest risk of IDA. The health expenditures of IDA have also increased; IDA was commonly accompanied by diseases of the respiratory or gastrointestinal tract.

The overall IDA prevalence increased in both males and females from 2002 to 2013. The greatest increase was evident in those aged \<10 years, probably caused by inappropriate feeding and growth spurts in infants and children, and/or the mother's low iron status during pregnancy. Infants aged ≥6 months cannot obtain sufficient iron via breastfeeding alone; they lack iron stores adequate for growth spurts \[[@B21-ijerph-17-04433]\]. Generally, breastfed infants require iron-fortified weaning when aged ≥ 2 months. However, many homemade weaning formulae have low iron contents \[[@B22-ijerph-17-04433]\]. Furthermore, the early use of cow's milk may explain the rapid increase in IDA prevalence. Such milk is recommended for those aged \>14 months; however, 6.6% of Korean infants are fed cow's milk when aged \<12 months \[[@B23-ijerph-17-04433],[@B24-ijerph-17-04433]\]. IDA can also be prevalent in children. The KNHANES found that the iron intake of preschool children was 7.0 mg/day, 79.8% below the recommended level, explaining the high risks of IDA in infants and children in Korea \[[@B25-ijerph-17-04433]\]. Furthermore, the prevalence of anemia ranges from around 20--30% in pregnant women in Korea \[[@B26-ijerph-17-04433],[@B27-ijerph-17-04433]\]. Maternal iron deficiency may contribute to low iron stores during infancy, causing an increase in IDA in infants and toddlers if not treated properly.

The IDA prevalence also increased notably in the elderly. The KNHANES III (1988--1994) surveyed \>5000 community-dwelling elderly subjects. In the USA, 11.0% of males and 10.2% of females aged ≥65 years were anemic \[[@B28-ijerph-17-04433]\]. Of the various anemias, IDA was the most common (25.4%) \[[@B29-ijerph-17-04433]\]. The marked increase in IDA prevalence in those aged ≥ 80 years may be associated with chronic diseases and/or poor dietary habits. The prevalence of chronic diseases that are attributable to IDA in the elderly is increasing in Korea. IDA is often accompanied by chronic inflammatory diseases (e.g., rheumatoid arthritis, tuberculosis, myelitis, malignancy, or liver/renal disease) in the elderly \[[@B30-ijerph-17-04433]\]. Poor appetite and decreased digestive function and/or digestive system diseases, reported as frequent co-morbidities in our study, also reflect poor nutrient digestion and absorption in the elderly. The "tea and toast lady syndrome", a form of malnutrition in elderly subjects who are unable to prepare meals but nonetheless seek to feed themselves, can cause IDA \[[@B31-ijerph-17-04433]\]. The number of elderly subjects living alone increased 1.8-fold from 2005 to 2015. Elderly subjects who have seldom cooked by themselves, and who lack the ability to cook a nutritionally balanced menu, develop nutritional deficiencies including IDA. Since aging of Korea and amounts of elderly people living alone are increasing rapidly, supplying balanced meals to the elderly is very important to prevent and manage disease.

Notably, IDA was most common in females aged 40--49 years, followed by those aged 30--39 years. The higher prevalence of IDA in these age groups may be caused by pregnancy and postpartum issues. IDA accounts for about 75% of all cases of anemia during pregnancy; the iron supply is inadequate \[[@B32-ijerph-17-04433]\]. The maternal iron demand is 24 mg/day during the second part of pregnancy, but most Korean women commence pregnancy with minimal iron stores during the second trimester, with the average iron intake of 19.1 mg/day \[[@B33-ijerph-17-04433]\]. Untreated IDA during pregnancy is aggravated by blood loss during delivery, IDA can continue into the postpartum period, and indeed into the fifth decade of life \[[@B34-ijerph-17-04433]\]. Furthermore, IDA in females aged 30--39 and 40--49 is perhaps associated with abnormal uterine bleeding (AUB) accompanied by uterine myomas or endometrial polyps \[[@B35-ijerph-17-04433]\]. AUB is the most common cause of IDA in pre-menopausal women, and the risk increases in those aged ≥35 years \[[@B35-ijerph-17-04433],[@B36-ijerph-17-04433]\]. The reason for the high rate of IDA prevalence in females aged 30--49 is expected to include pregnancy and breastfeeding, but more accurate classification of the causes is needed. Since the iron consumption or demand of this age group is different, it is a very important point of view for establishing policies for the prevention of IDA.

We present reliable data on the health expenditures imposed by IDA, i.e., both the direct medical and direct non-medical costs. These costs increased 2.4--2.9 fold over 12 years, probably attributable to an increase in IDA prevalence. Notably, outpatient costs increased continuously, being 6.2-fold those of hospitalization in 2013. Recent advances in health examination strategies allow detection of mild IDA treatable in outpatient settings.

IDA was accompanied by conditions of the respiratory and gastrointestinal tracts in both sexes. Iron status plays a key role in upper/lower respiratory tract infections and diseases such as the common cold, pneumonia, and asthma \[[@B37-ijerph-17-04433],[@B38-ijerph-17-04433],[@B39-ijerph-17-04433]\]. Although the reason is unclear, it is possible that IDA impairs the defense mechanisms of the airway mucosa \[[@B40-ijerph-17-04433]\]. Furthermore, gastrointestinal tract conditions may be accompanied by IDA because of increased iron loss (e.g., via melena, hematemesis, or rectal or invisible bleeding) and decreased iron absorption (e.g., in those with celiac disease or atrophic gastritis, and those of postsurgical status) \[[@B41-ijerph-17-04433],[@B42-ijerph-17-04433]\]. Both physicians and IDA patients should be aware of the risks and act accordingly.

Our study had certain limitations. First, for the period 2002--2005, the NHIS database contains information on only NHI beneficiaries, and not MA beneficiaries. Therefore, IDA prevalence may have been underestimated \[[@B12-ijerph-17-04433]\]. There is another reason why the IDA prevalence rate is estimated to be low. The actual prevalence rate would have been underestimated as those who did not receive medical diagnosis or treatment were excluded from the claim. In other words, they may have been omitted from the diagnosis because they have already been treated or medicated and have not actually visited the hospital due to IDA. Second, we did not consider disease severity (as reflected by the hemoglobin level), although the costs associated with mild, moderate, and severe IDA differ. Third, we included only traffic cost of patient and caregiver for the estimation of direct non-medical cost, excluding caregiver's economic costs for patient care. Therefore, economic cost might be underestimated. Finally, the analysis date was compliant with the data provision criteria of the Korea National Health Insurance Service, but it is currently somewhat old data, and biological observations have not been reflected. We need to maintain continuous trend analysis in the future. On the other hand, our research has differences and strengths compared to previous studies. Since the source of our data is Korean medical claim data, objectivity is secured, and the prevalence rate of IDA patients is calculated most accurately. This is the first nationwide study on the disease burden in Korea. In the case of Korea, an iron supplement support project is being implemented from a community health perspective, and the NutriPlus program, an iron-rich food delivery service, is being implemented for pregnant women, breastfeeding women, or infants. However, because these services are supported by economic income or by applicants only, not by iron deficiency, only some of them are eligible. To prevent and treat IDA, the government needs to make efforts to select more accurate targets and expand standards of support.

In conclusion, IDA remains a debilitating nutritional problem in terms of public health nutrition in Korea, the annual prevalence of which continues to rise in association with adverse health expenditures and co-morbidities. Infants and young children, the elderly, and females aged 30--49 years are at highest risk. A national, prospective and well-organized effort to improve iron status and nutrition monitoring systems to manage IDA are required.
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###### 

Distribution in the sample cohort population and IDA-diagnosed patients, 2002--2013.

  Variable                     2002        2003        2004        2005        2006        2007        2008        2009      2010        2011        2012        2013
  ---------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- --------- ----------- ----------- ----------- -----------
  No. of Total population \*                                                                                                                                     
  All                          1,025,340   1,017,468   1,016,580   1,016,820   1,002,005   1,020,743   1,000,785   998,527   1,006,481   1,011,123   1,014,730   1,014,730
  Male                         513,258     509,212     508,223     508,317     500,808     510,009     501,019     499,689   503,428     505,614     507,289     507,289
  Female                       512,082     508,256     508,357     508,503     501,197     510,734     499,766     498,838   503,053     505,509     507,441     507,441
  No. of IDA population \*\*                                                                                                                                     
  All                          3188        3806        4467        5049        5289        5730        6390        6575      6757        7286        7468        7325
  Male                         579         671         780         917         981         1047        1325        1298      1331        1493        1497        1523
  Female                       2609        3135        3687        4132        4308        4683        5065        5277      5426        5793        5971        5802

\* Residence-registration mid-year population from Korean Statistical Information Service (KOSIS). \*\* Definition of IDA-diagnosed patients: subjects diagnosed as D50, D50.0, D50.8, or D50.9 as primary disease within that year.

ijerph-17-04433-t002_Table 2

###### 

Prevalence of iron deficiency anemia in Korea, 2002--2013.

  Variable                                Age-Standardized Prevalence Rates per 100,000 \* (%)                                                                                                                            
  --------------------------------------- ------------------------------------------------------ -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------ -------------- ---------
  No. of IDA patients (%)                                                                                                                                                                                                 
  All                                     313.6                                                  374.0    440.9    495.6    525.1    559.2    635.2    656.1    674.3    724.4    736.1    718.9    7.6    (5.9, 9.4)     \<0.001
  Male                                    117.7                                                  134.7    157.0    180.7    197.4    204.6    261.6    258.2    265.5    296.6    291.7    293.9    8.9    (7.1, 10.8)    \<0.001
  Female                                  507.6                                                  611.9    722.5    808.5    851.6    911.8    1008.5   1053.7   1083.7   1153.6   1182.9   1145.8   7.4    (5.6, 9.2)     \<0.001
  \<10                                    188.9                                                  279.0    306.5    415.2    494.4    610.0    885.5    1007.5   1057.9   1109.3   1173.1   1142.6   18.7   (14.6, 22.8)   \<0.001
  10--19                                  266.3                                                  261.2    296.3    322.9    347.1    321.5    379.9    392.9    409.7    469.0    481.9    460.2    5.9    (4.9, 6.9)     \<0.001
  20--29                                  292.7                                                  328.9    381.7    402.7    463.9    429.9    455.6    451.2    478.2    465.4    468.5    474.5    3.8    (2.1, 5.5)     \<0.001
  30--39                                  415.0                                                  469.8    564.2    651.9    643.8    694.8    715.1    746.8    714.2    739.6    699.4    686.1    4.3    (2, 6.6)       0.002
  40--49                                  405.2                                                  555.6    652.8    708.7    768.8    827.9    949.1    934.3    991.2    1075.5   1067.5   1094.1   8.3    (6.1, 10.5)    \<0.001
  50--59                                  273.9                                                  300.1    379.4    430.4    454.1    476.3    502.4    506.5    523.8    555.7    594.0    526.7    6.3    (4.2, 8.4)     \<0.001
  60--69                                  225.1                                                  305.9    305.4    363.0    341.3    402.9    446.4    506.4    464.7    556.5    540.1    511.6    7.6    (5.6, 9.6)     \<0.001
  70--79                                  336.5                                                  369.6    480.9    528.6    536.9    572.1    690.9    638.7    714.7    819.4    885.3    811.7    8.6    (6.8, 10.3)    \<0.001
  ≥80                                     302.7                                                  328.7    469.7    465.2    443.9    595.6    668.1    829.9    837.1    946.0    1149.7   1191.0   13.5   (11.7, 15.3)   \<0.001
  No. of IDA patients among males (%)                                                                                                                                                                                     
  \<10                                    201.6                                                  267.1    327.1    468.0    483.7    655.4    996.9    1048.3   1148.2   1193.1   1264.1   1209.5   19.1   (14.8, 23.6)   \<0.001
  10--19                                  149.1                                                  130.7    124.0    172.4    182.6    156.8    187.9    140.1    174.7    191.6    159.3    168.4    2.0    (−0.4, 4.5)    0.098
  20--29                                  34.7                                                   58.2     65.2     71.4     89.2     55.6     95.3     89.6     91.6     118.7    78.6     95.9     7.2    (2.8, 11.8)    0.004
  30--39                                  58.4                                                   64.4     73.5     81.0     82.4     87.7     86.9     90.1     78.2     95.2     85.3     93.1     3.4    (1.7, 5.1)     0.001
  40--49                                  74.7                                                   83.6     109.5    93.9     130.2    101.7    123.8    112.6    104.9    151.0    127.6    147.0    4.9    (2.4, 7.6)     0.001
  50--59                                  109.8                                                  131.6    164.6    159.7    167.4    164.0    161.5    182.0    160.9    178.8    203.4    186.6    3.8    (1.9, 5.7)     0.001
  60--69                                  197.9                                                  226.3    242.9    272.6    247.0    313.8    367.9    389.5    363.5    428.3    415.2    413.8    7.4    (5.8, 9.1)     \<0.001
  70--79                                  311.6                                                  369.8    422.2    475.5    587.4    550.4    660.9    557.4    593.3    693.0    647.3    679.3    6.6    (4.2, 9)       \<0.001
  ≥80                                     341.4                                                  324.4    512.8    532.1    573.2    633.8    841.4    922.9    884.7    682.7    1027.2   1010.2   10.5   (7.1, 14)      0.001
  No. of IDA patients among females (%)                                                                                                                                                                                   
  \<10                                    174.8                                                  292.1    283.8    357.4    506.1    560.5    764.3    963.4    960.6    1019.3   1075.9   1071.3   18.2   (14.2, 22.3)   \<0.001
  10--19                                  395.6                                                  406.5    489.3    491.8    532.6    506.7    595.0    676.9    672.9    778.7    841.1    783.4    7.2    (6, 8.3)       \<0.001
  20--29                                  556.3                                                  605.1    703.6    742.5    848.8    815.8    831.1    829.8    886.9    836.3    889.1    887.5    3.8    (2.2, 5.4)     \<0.001
  30--39                                  787.7                                                  890.6    1072.1   1241.4   1220.6   1320.9   1370.9   1430.9   1375.4   1408.0   1335.8   1303.2   4.3    (2, 6.7)       0.002
  40--49                                  747.5                                                  1048.7   1218.5   1351.4   1439.3   1582.3   1804.0   1784.5   1911.5   2038.7   2045.9   2072.5   8.5    (6.2, 10.9)    \<0.001
  50--59                                  435.9                                                  467.8    595.4    700.5    740.9    789.8    847.1    834.9    889.1    934.5    987.7    872.5    6.9    (4.6, 9.3)     \<0.001
  60--69                                  247.8                                                  373.8    359.0    441.3    424.2    482.0    516.9    612.5    557.9    675.4    656.9    603.4    7.9    (5.5, 10.3)    \<0.001
  70--79                                  350.9                                                  369.5    516.5    561.7    505.1    586.2    711.2    695.0    800.2    910.0    1060.3   910.4    9.8    (7.9, 11.9)    \<0.001
  ≥80                                     287.1                                                  330.5    451.5    437.2    389.3    579.6    595.5    790.7    816.9    1057.2   1201.5   1268.0   14.7   (12.4, 17)     \<0.001

APC, annual percent change; CI, confidence interval; IDA, iron deficiency anemia. \* Adjusted to the sample cohort population in 2011.
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###### 

Female-to-male prevalence ratios of iron deficiency anemia in the sample cohort population, 2002--2013.

  Variable   PRR                                                                                                                                        
  ---------- ------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ---------------- ---------
             No. of IDA patients (%)                                                                                                                    
  All        4.52                      4.68    4.73    4.50    4.39    4.47    3.83    4.07    4.08    3.88    3.99    3.81    −0.08   (−0.11, −0.05)   \<0.001
  \<10       0.87                      1.09    0.87    0.76    1.05    0.86    0.77    0.92    0.84    0.85    0.85    0.89    −0.01   (−0.03, 0.01)    0.378
  10--19     2.65                      3.11    3.95    2.85    2.92    3.23    3.17    4.83    3.85    4.07    5.28    4.65    0.19    (0.08, 0.29)     0.003
  20--29     16.01                     10.39   10.80   10.40   9.52    14.68   8.73    9.26    9.68    7.05    11.31   9.25    −0.36   (−0.78, 0.06)    0.083
  30--39     13.49                     13.82   14.59   15.33   14.81   15.06   15.78   15.89   17.58   14.79   15.65   14.01   0.14    (−0.06, 0.33)    0.151
  40--49     10.00                     12.55   11.13   14.39   11.05   15.56   14.58   15.85   18.22   13.51   16.03   14.09   0.44    (0.09, 0.79)     0.02
  50--59     3.97                      3.55    3.62    4.39    4.43    4.82    5.25    4.59    5.52    5.23    4.86    4.68    0.13    (0.05, 0.21)     0.005
  60--69     1.25                      1.65    1.48    1.62    1.72    1.54    1.40    1.57    1.53    1.58    1.58    1.46    0.00    (−0.02, 0.03)    0.667
  70--79     1.13                      1.00    1.22    1.18    0.86    1.07    1.08    1.25    1.35    1.31    1.64    1.34    0.04    (0.01, 0.07)     0.016
  ≥80        0.84                      1.02    0.88    0.82    0.68    0.91    0.71    0.86    0.92    1.55    1.17    1.26    0.04    (0.00, 0.08)     0.048

PRR, prevalence rate ratio; CI, confidence interval; IDA, iron deficiency anemia.
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###### 

Health Expenditures of iron deficiency anemia in Korea, 2002--2013.

  Year   Category          Direct Medical Cost (①)   Direct Non-Medical Cost (②)   Total Cost                                
  ------ ----------------- ------------------------- ----------------------------- ------------ --------- -------- --------- ------
         Outpatient        78,081                    850                           31,957       110,888   4760     115,648   42
  2002   Hospitalization   71,137                    4194                          12,763       88,094    6461     94,555    100
         Total             149,218                   5044                          44,720       198,982   11,221   210,203   66
         Outpatient        89,058                    2050                          38,954       130,062   5978     136,040   43
  2003   Hospitalization   94,958                    5003                          20,650       120,611   8781     129,392   101
         Total             184,017                   7054                          59,604       250,675   14,760   265,435   70
         Outpatient        111,484                   2730                          49,281       163,495   7640     171,135   46
  2004   Hospitalization   124,980                   9985                          24,609       159,574   11,257   170,831   116
         Total             236,464                   12,715                        73,891       323,070   18,898   341,968   77
         Outpatient        137,784                   2571                          58,248       198,603   9316     207,919   48
  2005   Hospitalization   148,801                   10,436                        24,223       183,460   12,198   195,658   126
         Total             286,585                   13,008                        82,472       382,065   21,514   403,579   80
         Outpatient        153,628                   3997                          67,726       225,351   10,517   235,868   52
  2006   Hospitalization   152,398                   9168                          27,536       189,102   12,347   201,449   131
         Total             306,027                   13,165                        95,262       414,454   22,865   437,319   83
         Outpatient        188,227                   9566                          83,559       281,352   13,691   295,043   57
  2007   Hospitalization   138,447                   9040                          19,244       166,731   9481     176,212   156
         Total             326,674                   18,607                        102,803      448,084   23,172   471,256   82
         Outpatient        207,482                   7186                          99,692       314,360   17,109   331,469   56
  2008   Hospitalization   126,886                   11,622                        13,359       151,867   7576     159,443   199
         Total             334,368                   18,808                        113,052      466,228   24,686   490,914   77
         Outpatient        226,668                   7983                          101,786      336,437   17,975   354,412   58
  2009   Hospitalization   128,694                   7186                          14,725       150,605   8127     158,732   186
         Total             355,363                   15,170                        116,512      487,045   26,103   513,148   78
         Outpatient        229,509                   2788                          108,159      340,456   18,623   359,079   57
  2010   Hospitalization   131,289                   8186                          16,737       156,212   8386     164,598   201
         Total             360,799                   10,974                        124,896      496,669   27,009   523,678   78
         Outpatient        299,233                   12,686                        122,536      434,455   22,540   456,995   67
  2011   Hospitalization   152,304                   11,759                        13,164       177,227   7835     185,062   240
         Total             451,538                   24,445                        135,700      611,683   30,375   642,058   88
         Outpatient        338,735                   11,575                        129,016      479,326   26,847   506,173   68
  2012   Hospitalization   96,617                    7167                          34           103,818   1042     104,860   1008
         Total             435,353                   18,743                        129,050      583,146   27,890   611,036   82
         Outpatient        356,314                   11,739                        118,925      486,978   26,093   513,071   71
  2013   Hospitalization   78,594                    3576                          7            82,177    1005     83,182    990
         Total             434,909                   15,316                        118,932      569,157   27,099   596,256   81

Unit: USD.

[^1]: These authors contributed equally to this work as first author.
